Core Viewpoint - Catheter Precision, Inc. has secured its first purchase order and a multi-year commitment for its LockeT device at Mater Private Hospital, Ireland's largest electrophysiology center, marking a significant step in the company's global expansion strategy and commitment to enhancing cardiac care safety and efficiency [1][4]. Group 1: Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for cardiac arrhythmias, emphasizing collaboration with physicians to advance electrophysiology procedures [6]. - The LockeT device is a suture retention device designed to assist in wound closure after percutaneous venous punctures, classified as a Class 1 device registered with the FDA and has received CE Mark approval [5]. Group 2: Product Implementation - The implementation of LockeT at Mater Private Hospital involved a rapid onboarding process, with the chief nurse training 52 staff members in just two days, highlighting the device's intuitive design and operational efficiency [3]. - Mater Private Hospital performs over 1,000 electrophysiology procedures annually, making it a crucial institution for arrhythmia treatment and innovation in Europe [2]. Group 3: Strategic Importance - The partnership with Mater Private Dublin is viewed as a major achievement for Catheter Precision, validating the technology and strengthening its position in the global electrophysiology market [4]. - The acceptance of LockeT at this hospital underscores the company's focus on expanding its international market presence and promoting technologies that enhance clinical outcomes [4].
Catheter Precision (VTAK) Announces Expansion of LockeT into an Eighth European Country Since Receipt of CE Mark